DUONEB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DUONEB (DUONEB).
DUONEB is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors in bronchial smooth muscle, reducing vagal tone and bronchodilation. Albuterol stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle.
| Metabolism | Ipratropium is minimally absorbed and partially metabolized by ester hydrolysis to inactive metabolites. Albuterol is primarily metabolized by sulfation (not CYP450) to albuterol 4'-O-sulfate. |
| Excretion | DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal. |
| Half-life | Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours. |
| Protein binding | Ipratropium: 0-9% bound to plasma proteins. Albuterol: 50-60% bound, primarily to albumin. |
| Volume of Distribution | Ipratropium: Vd ~4.6 L/kg (large, extensive tissue distribution). Albuterol: Vd ~2.3 L/kg (distributes into tissues, including placenta and breast milk). |
| Bioavailability | Inhalation: Ipratropium 7-28% (mean 18%); Albuterol 10-20%. Oral (swallowed): Ipratropium <1%; Albuterol ~50% but not used clinically. |
| Onset of Action | Inhalation: Ipratropium onset 15-30 minutes (peak 1-2 hours); Albuterol onset 5-15 minutes (peak 30-90 minutes). |
| Duration of Action | 4-6 hours for bronchodilation. Clinical note: Combination provides additive effect with longer duration than albuterol alone in some patients. |
| Molecular Weight | Ipratropium: 412.4 Da; Albuterol: 239.3 Da |
1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, data insufficient but caution advised; consider monitoring for adverse effects. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for increased systemic exposure. |
| Pediatric use | Children <12 years: not recommended; children ≥12 years: same as adult dosing. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased anticholinergic side effects and reduced renal function. |
| 1st trimester | Limited human data; no teratogenicity in animal studies. Use only if clearly needed. |
| 2nd trimester | No known risk in human studies; consider benefit vs risk. |
| 3rd trimester | May cause uterine relaxation and delay labor; use cautiously near term. |
Clinical note
Comprehensive clinical and safety monograph for DUONEB (DUONEB).
| Placental transfer | Both ipratropium and albuterol cross the placenta; ipratropium has minimal transfer, albuterol has moderate transfer. |
| Breastfeeding | Excreted into breast milk in low concentrations; unlikely to cause adverse effects in infant. Caution with high doses. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to ipratropium, albuterol, or any componentHistory of hypersensitivity to atropine or its derivatives
| Precautions | Paradoxical bronchospasm may occur; discontinue immediately if occurs., Cardiovascular effects (increased heart rate, blood pressure, ECG changes) with albuterol; use with caution in patients with cardiovascular disorders., Immediate hypersensitivity reactions (urticaria, angioedema, rash) may occur., Albuterol may cause hypokalemia when used with diuretics or steroids., Not indicated for acute deterioration of COPD; single-strength formulation is not for acute attacks. |
| Food/Dietary | No clinically significant food interactions. Avoid excessive caffeine intake as it may increase side effects like nervousness and palpitations. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Ipratropium and albuterol sulfate are both Pregnancy Category C. Ipratropium: No teratogenic effects in animal studies; insufficient human data; risk cannot be ruled out. Albuterol: Associated with increased fetal heart rate and hypoglycemia in newborns when used in preterm labor; no evidence of teratogenicity in humans at therapeutic doses. Use only if clearly needed. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and serum potassium; fetal heart rate monitoring in cases of maternal tachycardia or if used for preterm labor. Assess for signs of maternal hypokalemia or hyperglycemia. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies with albuterol have shown no impairment of fertility. |
| Clinical Pearls | DuoNeb (ipratropium/albuterol) is a fixed-dose combination of an anticholinergic and a beta-2 agonist. It is indicated for maintenance treatment of COPD, including chronic bronchitis and emphysema. Not indicated for acute exacerbations. Should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction. Monitor for paradoxical bronchospasm. Instruct patient to avoid contact with eyes as it may cause blurred vision and mydriasis. |
| Patient Advice | Use exactly as prescribed; do not exceed recommended dose. · Rinse mouth with water after each use to prevent oral thrush and dryness. · Report worsening symptoms, chest tightness, or rapid heartbeat immediately. · Avoid spraying into eyes; if contact occurs, rinse with water and seek medical advice. · Do not use other inhaled medications unless directed by your healthcare provider. |